Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. - Wikidata - wikimedia - TriplyDB

Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.

Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.

http://www.wikidata.org/entity/Q38266308

about

Tyrosine Kinase Inhibitors for the Elderly Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer Caspase 8 polymorphisms contribute to the prognosis of advanced lung adenocarcinoma patients after platinum-based chemotherapy.Prognostic significance of G2/M arrest signaling pathway proteins in advanced non-small cell lung cancer patients KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.Upregulation of miR-1280 expression in non-small cell lung cancer tissues Characterization of different CTC subpopulations in non-small cell lung cancer.EGFR with TKI-sensitive mutations in exon 19 is highly expressed and frequently detected in Chinese patients with lung squamous carcinoma.Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network.Significance and evaluation of anaplastic lymphoma kinase by immunohistochemistry in non-small cell lung cancer.

P2860

Q26748567-D25BDC26-472C-4AB7-BBE3-0E95BA28A90C Q26771116-22DF6C9E-B83F-4F1E-A5F7-25B2677C696A Q33439990-A6B58690-5A7F-48D7-B05A-EB09EFE7EFD1 Q35042074-09E9318C-D042-402F-BC47-27A32238E368 Q36369197-56DAA48C-0BA9-4632-B8D4-43BC6FAAC90A Q36807177-0C640C09-F99A-4476-B53B-66B498AA82BB Q37005619-E32D3F56-2167-409A-97A0-D27A911A1291 Q42731684-961C85B4-C3FB-4B05-8F19-D418D65766FF Q48841438-2B5D4663-C292-4FFA-AF5E-BE57489F5B00 Q55030710-AC79B45F-5009-42E1-A49A-589A8D3B530F

P2860

Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.

http://www.wikidata.org/entity/Q38266308

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.

@en

type

label

Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.

@en

prefLabel

Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.

@en

P1433

Q38266308-85F24C86-DA37-4552-A079-89660755CE19

P1476

Q38266308-88CEABF0-7F1B-4AFE-8377-8E8E0E0C4375

P2093

Q38266308-670D5A89-E8F7-45B5-9B66-553AF62A9731

Q38266308-F9F55707-6D91-43D7-B6D6-5F5189C58F84

P2860

Q38266308-009D9194-340F-4CD1-9625-7B9F6B863DF2

Q38266308-00A41D5B-F523-4AB4-AD9E-DF4F19D6F300

Q38266308-0345CD08-2822-4632-AE42-5C5DF7AEE3E0

Q38266308-03501541-B2FA-4422-B55B-39B527299024

Q38266308-067735DD-8637-4211-AF01-2E4786D99F3A

Q38266308-0A39345D-E6C1-4E15-9628-791E079B56E0

Q38266308-0EF6109B-A3FD-4E9E-9A3A-D80B9CF54B28

Q38266308-18A63F7F-BA34-4C6F-810C-747A8377B572

Q38266308-1BC2FAD6-FD80-41E4-8FE7-3209FD8D7220

Q38266308-226EC198-70F7-4C0E-89A3-C54EE6EC77E9

P304

Q38266308-D6B32954-8754-4389-972E-5CCC502176C5

P31

Q38266308-565B73A3-0D9D-40FE-8DD2-65B5C283D935

P356

Q38266308-3B06DA4D-31C1-48A4-A87F-D7D5B221AB9D

P407

Q38266308-038177DA-FE81-47A6-B1E6-83053357D361

P433

Q38266308-9A5228AD-F670-4B8B-A34A-C3AA52337489

P478

Q38266308-02E94960-AB6C-48E5-A2DA-296107FAABE7

P50

Q38266308-80AE7802-E04C-40A6-BFD2-CC6C5864C3D1

P577

Q38266308-26D46E7B-8688-47D0-B84E-8A3B07F9B489

P698

Q38266308-1C8A91DD-E95A-41BF-8FEC-AECD40C0C6CE

P356

14656566.2014.971013

P1433

Expert Opinion on Pharmacotherapy

P1476

Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.

@en

P2093

Mark A Socinski

http://www.w3.org/2001/XMLSchema#string

Timothy F Burns

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

P304

2693-2708

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2014.971013

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Ashwin Somasundaram

P577

2014-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25381900

http://www.w3.org/2001/XMLSchema#string